Ajanta Pharma stands as a distinguished player in the pharmaceutical industry, known for its commitment to delivering high-quality medicines across more than 30 countries worldwide. With a focus on innovation and customer-centricity, the company has secured leadership positions in multiple molecules and therapeutic segments through its pioneering first-to-market products. Its business model, which includes Branded Generics in India and Emerging Markets, Generics in the USA, and Institution Sales in Africa, ensures scalability and sustainability. Ajanta Pharma’s relentless pursuit of meeting patient needs drives its development of differentiated first-to-market products, further solidifying its position in various therapeutic segments. Operating state-of-the-art manufacturing facilities in India, with stringent quality standards approved by regulatory authorities, the company has built a reputation for trust and reliability among healthcare professionals and patients globally. With a strong focus on research and development and a diverse workforce of over 7,700 individuals from various nationalities, Ajanta Pharma remains steadfast in its mission to serve global healthcare needs through empathy, innovation, and technology.
Ajanta Pharmaceuticals Reports Robust Q4 Results with 65.82% Increase in Profit Year-on-Year
- Ajanta Pharmaceuticals announced its Q4 results on May 2, 2024, revealing a significant increase in profit by 65.82% YoY.
- The company experienced robust topline growth of 19.53%, although revenue declined by 4.62% compared to the previous quarter.
- Selling, general & administrative expenses rose slightly by 0.93% q-o-q and increased by 4.41% Y-o-Y.
- Operating income showed mixed performance, declining by 15.07% q-o-q but registering a substantial increase of 50.12% Y-o-Y.
- The EPS for Q4 stood at ₹16.09, marking a notable rise of 68.63% Y-o-Y.
- Ajanta Pharmaceuticals reported positive returns of 4.7% in the last 1 week, 22.16% in the last 6 months, and 7.22% YTD.
- The company’s market cap is ₹28129.56 Cr with a 52-week high/low of ₹2353.95 & ₹1235.89 respectively.
How to Purchase Ajanta Pharma
Below are the trading platforms that you can use to purchase Ajanta Pharma shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
Ajanta Pharma Share Price Prediction 2024, 2025 to 2030
Ajanta Pharma Share Price Prediction 2024
| When | Maximum Price | Minimum Price |
| July 2024 | 2,267.80 | 1,972.00 |
| August 2024 | 2,358.52 | 2,050.88 |
| September 2024 | 2,452.86 | 2,132.92 |
| October 2024 | 2,404.76 | 2,091.10 |
| November 2024 | 2,500.95 | 2,174.74 |
| December 2024 | 2,525.96 | 2,196.49 |
For the year 2024, Ajanta Pharma’s maximum and minimum prices are projected to reach significant levels. By July, the maximum price is expected to be ₹2,267.80, with a minimum price of ₹1,972.00. By December, the maximum price is anticipated to rise to ₹2,525.96, while the minimum is projected to be ₹2,196.49.
Ajanta Pharma Share Price Prediction 2025
| When | Maximum Price | Minimum Price |
| January 2025 | 2,551.22 | 1,962.48 |
| February 2025 | 2,576.99 | 1,982.30 |
| March 2025 | 2,631.11 | 2,023.93 |
| April 2025 | 2,605.06 | 2,003.89 |
| May 2025 | 2,529.18 | 1,945.52 |
| June 2025 | 2,643.00 | 2,033.07 |
| July 2025 | 2,591.17 | 1,993.21 |
| August 2025 | 2,671.31 | 2,054.85 |
| September 2025 | 2,703.37 | 2,079.51 |
| October 2025 | 2,773.65 | 2,133.58 |
| November 2025 | 2,843.00 | 2,186.92 |
| December 2025 | 2,970.93 | 2,285.33 |
In 2025, Ajanta Pharma’s stock prices are anticipated to show substantial fluctuations. In January, the maximum price is projected to reach ₹2,551.22, while the minimum could be ₹1,962.48. By December, the maximum price is expected to climb to ₹2,970.93, with the minimum price at ₹2,285.33.
Ajanta Pharma Share Price Prediction 2026
| When | Maximum Price | Minimum Price |
| January 2026 | 3,060.06 | 2,353.89 |
| February 2026 | 2,983.56 | 2,295.04 |
| March 2026 | 3,043.23 | 2,340.94 |
| April 2026 | 3,105.33 | 2,388.72 |
| May 2026 | 3,074.59 | 2,365.07 |
| June 2026 | 3,151.45 | 2,424.19 |
| July 2026 | 3,089.66 | 2,376.66 |
| August 2026 | 3,185.22 | 2,450.17 |
| September 2026 | 3,248.92 | 2,499.17 |
| October 2026 | 3,333.39 | 2,564.15 |
| November 2026 | 3,416.73 | 2,628.25 |
| December 2026 | 3,502.15 | 2,693.96 |
Ajanta Pharma Share Price Target 2027
| When | Maximum Price | Minimum Price |
| January 2027 | 3,537.17 | 2,720.90 |
| February 2027 | 3,627.86 | 2,790.66 |
| March 2027 | 3,769.35 | 2,899.50 |
| April 2027 | 3,695.44 | 2,842.65 |
| May 2027 | 3,587.81 | 2,759.85 |
| June 2027 | 3,749.26 | 2,884.05 |
| July 2027 | 3,675.74 | 2,827.50 |
| August 2027 | 3,789.43 | 2,914.94 |
| September 2027 | 3,922.06 | 3,016.97 |
| October 2027 | 4,024.03 | 3,095.41 |
| November 2027 | 4,124.63 | 3,172.79 |
| December 2027 | 4,227.75 | 3,252.11 |
Ajanta Pharma Share Price Prediction 2028
| When | Maximum Price | Minimum Price |
| January 2028 | 4,312.30 | 3,317.16 |
| February 2028 | 4,422.87 | 3,402.21 |
| March 2028 | 4,595.37 | 3,534.90 |
| April 2028 | 4,505.26 | 3,465.59 |
| May 2028 | 4,374.04 | 3,364.65 |
| June 2028 | 4,570.87 | 3,516.05 |
| July 2028 | 4,481.25 | 3,447.11 |
| August 2028 | 4,619.84 | 3,553.72 |
| September 2028 | 4,781.54 | 3,678.10 |
| October 2028 | 4,905.86 | 3,773.74 |
| November 2028 | 5,028.50 | 3,868.08 |
| December 2028 | 5,154.21 | 3,964.78 |
Ajanta Pharma Share Price Prediction 2029
| When | Maximum Price | Minimum Price |
| January 2029 | 5,257.30 | 4,044.08 |
| February 2029 | 5,392.10 | 4,147.77 |
| March 2029 | 5,602.39 | 4,309.53 |
| April 2029 | 5,492.54 | 4,225.03 |
| May 2029 | 5,332.57 | 4,101.97 |
| June 2029 | 5,572.53 | 4,286.56 |
| July 2029 | 5,463.27 | 4,202.51 |
| August 2029 | 5,632.23 | 4,332.49 |
| September 2029 | 5,829.36 | 4,484.12 |
| October 2029 | 5,980.92 | 4,600.71 |
| November 2029 | 6,130.45 | 4,715.73 |
| December 2029 | 6,283.71 | 4,833.62 |
Ajanta Pharma Share Price Target 2030
| When | Maximum Price | Minimum Price |
| January 2030 | 6,409.38 | 4,930.29 |
| February 2030 | 6,573.73 | 5,056.71 |
| March 2030 | 6,830.10 | 5,253.92 |
| April 2030 | 6,696.18 | 5,150.91 |
| May 2030 | 6,501.14 | 5,000.88 |
| June 2030 | 6,793.70 | 5,225.92 |
| July 2030 | 6,660.49 | 5,123.45 |
| August 2030 | 6,866.48 | 5,281.91 |
| September 2030 | 7,106.81 | 5,466.77 |
| October 2030 | 7,291.58 | 5,608.91 |
| November 2030 | 7,473.87 | 5,749.13 |
| December 2030 | 7,660.72 | 5,892.86 |
Ajanta Pharma’s stock prices are projected to exhibit significant variation. In January, the maximum price is expected to reach ₹6,409.38, while the minimum could be ₹4,930.29. By December, the maximum price is anticipated to rise to ₹7,660.72, with the minimum price at ₹5,892.
Ajanta Pharma Financial Condition
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 |
| Expenses + | 1,904 | 1,889 | 2,408 | 2,934 | 3,037 |
| Operating Profit | 683 | 1,001 | 933 | 808 | 1,172 |
| OPM % | 26% | 35% | 28% | 22% | 28% |
| Other Income + | 88 | 24 | 112 | 74 | 85 |
| Interest | 12 | 8 | 10 | 6 | 7 |
| Depreciation | 96 | 116 | 125 | 131 | 135 |
| Profit before tax | 664 | 900 | 909 | 745 | 1,114 |
| Tax % | 30.00% | 27.00% | 22.00% | 21.00% | 27.00% |
| Net Profit + | 468 | 654 | 713 | 588 | 816 |
| EPS in Rs | 35.73 | 50.38 | 55.63 | 45.89 | 64.82 |
| Dividend Payout % | 24.00% | 13.00% | 11.00% | 15.00% | 79.00% |
- Sales: Ajanta Pharma’s sales have exhibited consistent growth over the past five years, increasing from ₹2,588 crores in March 2020 to ₹4,209 crores in March 2024, representing a steady upward trend.
- Expenses: While expenses also grew over the period, they have been managed effectively relative to sales growth. Despite fluctuations, expenses remained under control, allowing the company to maintain healthy profit margins.
- Operating Profit: The operating profit fluctuated over the years but generally remained robust, reflecting the company’s ability to generate profits from its core operations. Operating profit peaked at ₹1,172 crores in March 2024, indicating operational efficiency.
- Other Income: Ajanta Pharma supplemented its operating income with other sources of revenue, such as investments and non-core activities. Other income remained relatively stable, contributing to overall profitability.
- Net Profit: The net profit showed an increasing trend, reaching ₹816 crores in March 2024. Despite fluctuations, the company managed to sustain profitability, indicating effective management and operational resilience.
- EPS (Earnings Per Share): Ajanta Pharma’s EPS increased consistently over the years, reflecting growing profitability and creating value for shareholders. The EPS rose from ₹35.73 in March 2020 to ₹64.82 in March 2024, demonstrating healthy earnings growth.
- Dividend Payout: The dividend payout percentage fluctuated significantly, reaching 79.00% in March 2024. This indicates the company’s commitment to rewarding shareholders with higher dividends as profits increase.
Overall, Ajanta Pharma’s financials reflect a company with a strong revenue trajectory, effective cost management, and consistent profitability, positioning it well for future growth and value creation.
Ajanta Pharma’s Share Price Target by Experts
ICICI Direct on Ajanta Pharma’s Shares Price
ICICI Direct recommends purchasing Ajanta Pharma shares, with a target price set at ₹2875.00
BOB Capital Markets Ltd on Ajanta Pharma’s Shares Price
BOB Capital Markets Ltd advises investors to buy Ajanta Pharma shares, setting a target price of ₹2585.00
FAQS
What is the current share price of Ajanta Pharma?
As of July 11th, 2024, the share price of Ajanta Pharma is around INR ₹2,244.
What is the expected share price target of Ajanta Pharma by 2024?
Based on various market analyses and expert opinions, the expected share price target of Ajanta Pharma by 2024 is around INR 2,525.96.
Can Ajanta Pharma‘s share price reach INR 5000 by 2025?
It is unlikely for the share price of Ajanta Pharma to reach INR 5000 by 2025. Such a target would require a massive and unrealistic growth rate.
What is Ajanta Pharma‘s share price target for 2025?
As per our analysis, Ajanta Pharma in 2025 is expected to trade between ₹1,962.48 and ₹2,970.93.
What is Ajanta Pharma‘s share price target for 2030?
As per our analysis, Ajanta Pharma’s share price target for 2030 would be somewhere between ₹4,930.29 and ₹7,660.72.
ALSO READ:
- KOTAK MAHINDRA BANK LTD SHARE PRICE TARGET 2024 TO 2030: CAN KOTAK MAHINDRA REACH 10,000 INR?
- Sona BLW Precision Forgings Ltd Share Price Target 2024, 2025 to 2030
- Coforge Ltd Share Price Target 2024, 2025 to 2030
Conclusion
In conclusion, Ajanta Pharmaceuticals has demonstrated robust performance in its Q4 results, marked by impressive growth in profit and resilient topline expansion. Despite facing some challenges, the company’s ability to maintain profitability and deliver strong financial results reflects its operational efficiency and strategic agility. With positive returns and a consistent dividend payout ratio, Ajanta Pharmaceuticals continues to inspire confidence among investors and stakeholders. As it continues to innovate and expand its presence in the pharmaceutical industry, Ajanta Pharmaceuticals appears well-positioned for sustained growth and value creation in the future.
Leave a Reply